Niagen Bioscience Hits 300 Research Agreements, Expanding NAD+ Science — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience has surpassed 300 material transfer agreements (MTAs) with global institutions, supporting 45 published clinical studies on NAD+.
The program includes agreements with over 200 institutions across 34 countries, generating over $200 million in third-party research funding.
Key studies include Niagen's role in long COVID, ataxia telangiectasia (AT), and inflammatory conditions like psoriasis.
The company has received FDA Orphan Drug and Rare Pediatric Disease designations for NR in treating AT.

The big picture

Niagen Bioscience's milestone reflects the growing scientific and commercial interest in NAD+ as a key factor in healthy aging. The company's extensive research program positions it as a leader in the biotech space, with potential applications spanning metabolic health, neurodegeneration, and rare diseases. The strategic focus on independent, third-party funded research enhances credibility and market differentiation.

What we're watching

Research Expansion: Whether Niagen Bioscience can sustain the pace of new research agreements and studies across emerging therapeutic areas.
Regulatory Progress: How the FDA designations for NR in treating AT will impact Niagen's strategic positioning in rare diseases.
Market Penetration: The pace at which Niagen can expand into new delivery modalities, including topical and injectable applications.